Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 177

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 177
---
. Growth was reported in Europe (+ 30.6% CER) and the Rest of the World region (+46.7% CER, due mainly due to China), though the effect was partly offset by lower sales in the United States following the release of a glyceryl trinitrate. Thymoglobulin sales rose by 15.2% CER in 2023 to € 478 million, driven by the United States.

| SANOFIFORM 20-F2024 | 83 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

Eloctate generated net sales of € 471 million in 2023 , down 15.5% CER, due to the adoption of ALTUVIIIO and competitive pressures . Net sales of Aubagio fell by 52.6% CER in 2023 to € 955 million, mainly due to the arrival of generics. In the United States, where generics came on the market on March 12, 2023, Aubagio fell by 67.8% CER at € 460 million. In Europe, generic competition for Aubagio began at the end of September 2023. Cerdelga sales rose by 6.9% CER to € 298 million, with growth reported in the United States (+ 5.6% CER at € 164 million), Europe (+ 6.3% CER at € 118 million), and the Rest of the World region (+ 23.5% CER at € 16 million) as new patients adopted the product or switched treatment. Vaccines In 2023 , the vaccines posted total net sales of € 7,477 million, up 3.6% on a reported basis and 8.6% CER. T he main driver was the launch of Beyfortus, which more than offset slow sales of influenza vaccines . Sales of Influenza Vaccines decreased by 5.5% CER in 2023 to € 2,669 million, due to a slight reduction in vaccine uptake and increased competition in the United States. Polio/Pertussis/Hib Vaccines and boosters , posted net sales of € 2,766 million in 2023 ( +1.4% CER), reflecting the ongoing expansion of Vaxelis in the United States at the expense of pentavalent vaccines in the first series of infant vaccinations. In the